WO2011110478A1 - Dabigatran etexilate-containing pharmaceutical composition - Google Patents

Dabigatran etexilate-containing pharmaceutical composition Download PDF

Info

Publication number
WO2011110478A1
WO2011110478A1 PCT/EP2011/053236 EP2011053236W WO2011110478A1 WO 2011110478 A1 WO2011110478 A1 WO 2011110478A1 EP 2011053236 W EP2011053236 W EP 2011053236W WO 2011110478 A1 WO2011110478 A1 WO 2011110478A1
Authority
WO
WIPO (PCT)
Prior art keywords
solid solution
dabigatran etexilate
pharmaceutically acceptable
acceptable salt
hydrophilic polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2011/053236
Other languages
French (fr)
Inventor
Dominique Meergans
Jana Paetz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ratiopharm GmbH
Original Assignee
Ratiopharm GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ratiopharm GmbH filed Critical Ratiopharm GmbH
Priority to US13/583,273 priority Critical patent/US20130149346A1/en
Priority to JP2012556453A priority patent/JP2013521318A/en
Priority to EP11708231A priority patent/EP2545044A1/en
Priority to EA201201263A priority patent/EA201201263A1/en
Priority to CA2792273A priority patent/CA2792273A1/en
Publication of WO2011110478A1 publication Critical patent/WO2011110478A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to a pharmaceutical composition containing dabigatran etexiiate or a pharmaceutically acceptable salt thereof as active ingredient.
  • Dabigatran etexiiate (3-[(2- ⁇ [4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]- methyl ⁇ -1 -methyl-1 H-benzimidazole-5-carbonyl)-pyridine-2-yl-amino]-propionic acid ethyl ester) has the following chemical formula:
  • This active ingredient is already known from WO 98/37075.
  • the main indication field of said active ingredient is the postoperative prophylaxis of deep venous thromboses and the prophylaxis of strokes.
  • the solubility of the active ingredient in water is only 1.8 mg/ml. Moreover, the active ingredient has a strong pH-dependent solubility that is greatly increased in the acidic environment. This leads to the problem that conventional oral pharmaceutical compositions have large variations in the bioavailability since the solubility of the active ingredient depends on the pH value in the patient's stomach. This is particularly problematic with patients in whom the stomach pH value is changed by physiological variability, illness, or premedications (for example, PP inhibitors). There is therefore a need for oral pharmaceutical compositions of the active ingredient dabigatran etexiiate that provide a release that is independent from the pH value of the stomach and thus, provide bioavailability of the active ingredient.
  • WO 03/074056 suggests a pharmaceutical composition for oral application that comprises in addition to the active ingredient one or more pharmaceutically acceptable organic acids having a water solubility of >1 g/250 ml at 20°C.
  • the corresponding pharmaceutical compositions may cause incompatibilities in the patient, in particular if they already have a hyperacid stomach.
  • the addition of the organic acid restricts the possible amount of active ingredient in an appropriate tablet or capsule. This problem is further exacerbated by the fact that, as a rule, organic acids have only a low buffer capacity so that relatively large amounts of acid have to be added to cause a possible effect on the pH value of the ambience in dissolution of an appropriate tablet.
  • WO 03/074056 describes pharmaceutical compositions that are prepared by spraying a dispersion of active ingredient and binder onto a core.
  • the ratio of active ingredient to binder is 5: 1.
  • the active ingredient is therefore used in large excess.
  • the active ingredient particles substantially remain and are still present in the crystalline form used. This is substantiated by the x-ray diffraction powder pattern of the correspondingly prepared market product Pradaxa ® shown in figure 1 . There can be seen the characteristic peaks of the crystalline dabigatran etexilate.
  • WO 98/37075 discloses various polymorphs of the crystalline dabigatran etexilate mesylate.
  • WO 2005/023249 discloses pharmaceutical compositions of the active ingredient dabigatran etexilate with a lipophilic, pharmaceutical acceptable, liquid, solid, or semi-solid carrier system.
  • One method for the preparation of said pharmaceutical compositions is that a dispersion of active ingredient is prepared in the liquid (melted) carrier system under stirring. Under these conditions the active ingredient does not dissolve in the carrier system, but is present in the final composition as dispersion, i.e. as solid active ingredient particles embedded in the carrier system.
  • the formulation shall be easy to process and provide the active ingredient both in physically and chemically stable form.
  • the active ingredient dabigatran etexilate or a pharmaceutically acceptable salt thereof is provided in a non-crystalline form.
  • the present invention relates to dabigatran etexilate or a pharmaceutically acceptable salt thereof in non-crystalline form.
  • a particularly suitable pharmaceutically acceptable salt of the dabigatran etexilate is the mesylate salt, i.e. the salt of the methanesulfonic acid.
  • Crystalline forms can be distinguished from non-crystalline forms of the active ingredient for example by DSC measurements or x-ray diffraction powder patterns. Crystalline active ingredient particles show characteristic peaks in the x-ray diffraction powder pattern (see, for example figure 1 ) that do not occur in the non-crystalline form of the active ingredient.
  • the present invention provides two different non-crystalline forms of dabigatran etexilate or a pharmaceutically acceptable salt thereof.
  • it is a solid solution comprising a solid solvent and dabigatran etexilate or a pharmaceutically acceptable salt thereof dissolved therein.
  • the second embodiment provides the active ingredient in an amorphous form, this form being provided as a composition with one or more hydrophilic polymers to be stable.
  • the solid solution differs from the composition containing the amorphous form in that in the solid solution the active ingredient is present molecularly dispersed, whereas in the composition in addition to polymer particles there are present amorphous active ingredient particles.
  • the solid solution represents a mixture on a molecular level, whereas the composition represents a mixture of macroscopic particles.
  • a solid solution is herein understood a body that is solid at a temperature of 23°C and a pressure of 101 kPa wherein the components are homogenously distributed.
  • the active ingredient is molecularly dispersed in the solid solvent.
  • the solid solution is substantially free of active ingredient particles wherein herein substantially free of active ingredient particles means that at least 80 % by weight of the active ingredient are dissolved in the solvent, so is present molecularly dispersed, preferably at least 90 % by weight, more preferred at least 95 % by weight such as for example at least 99 % by weight.
  • the active ingredient is completely molecularly dispersed in the solvent. Any remaining active ingredient particles may be amorphous or crystalline.
  • the molecular dispersion of the active ingredient and thus the presence of a solution can be characterized for example by electron micrographs, DSC measurements, or by a decrease of the peaks characteristic for the crystalline active ingredient particles in the x-ray diffraction powder pattern in dissolution of the crystalline active ingredient particles in the solvent.
  • solid solvent those solvents that are present as a solid at a temperature of 23°C and a pressure of 101 kPa.
  • Suitable solid solvents for the active ingredient dabigatran etexilate or a pharmaceutical acceptable salt thereof are for example hydrophilic polymers. These can be used alone or mixed with one or more polymers.
  • hydrophilic polymer comprises polymers with polar groups.
  • polar groups are hydroxy, amino, carboxy, carbonyl, ethers, esters, and sulfonates. Hydroxy groups are particularly preferred.
  • the hydrophilic polymer has a water solubility of >0.01 mg/ml at 23°C.
  • the melting point of the hydrophilic polymer may be relevant.
  • the melting point of the hydrophilic polymer should be chosen such that it is below the melting point of the active ingredient to avoid an increased degradation of the active ingredient during processing.
  • the melting point of the hydrophilic polymer in this case should be ⁇ 140°C, more preferred ⁇ 120°C.
  • the polymer can be selected regardless of its melting point.
  • the hydrophilic polymer has an average molecular weight in the range between 1000 and 250,000 g/mol, preferably 2000 and 100,000 g/mol, and particularly preferred between 4000 and 85,000 g/mol.
  • a 2% (w/w) solution of the hydrophilic polymer in pure water has preferably a viscosity between 0.2 and 18 mPas at 25°C. The viscosity is determined in accordance to the European Pharmacopoeia (Ph. Eur.), 6 th edition, section 2.2.10.
  • the hydrophilic polymer has preferably a glass transition temperature (Tg) between 20°C and 220°C, preferably 25°C to 170°C.
  • the glass transition temperature (Tg) is the temperature at which the hydrophilic polymer becomes brittle on cooling and soft on heating. That means that the hydrophilic polymer becomes soft above the glass transition temperature and can be plastically deformed without breaking.
  • the glass transition temperature is determined by means of a Mettler- Toledo ® DSC 1 using a heating rate of 10°C/min. and a cooling rate of 15°C/min.
  • hydrophilic polymers examples include cellulose derivatives, in particular hydrophilic derivatives of the cellulose (e.g. hydroxypropylmethylcellulose (HPMC), carboxymethylcellulose, preferably as sodium or calcium salt, hydroxyethylcellulose (HEC), hydroxypropylcellulose (HPC)), starch, gum arabic, tragacanth gum, polyvinylpyrrolidone (PVP), preferably with a molecular weight of from 10,000 to 60,000 g/mol, copolymers of PVP, preferably co-polymers comprising vinylpyrrolidone and vinylacetate units (e.g.
  • HPMC hydroxypropylmethylcellulose
  • HEC hydroxyethylcellulose
  • HPC hydroxypropylcellulose
  • PVP polyvinylpyrrolidone
  • copolymers of PVP preferably co-polymers comprising vinylpyrrolidone and vinylacetate units (e.g.
  • povidone, VA64, BASF preferably with a molecular weight between 40,000 and 70,000 g/mol
  • Preferred hydrophilic polymers are polyethylene glycols, polyethylene glycol glycerides, block copolymers of ethylene oxide and propylene oxide, hydroxypropylmethylcellulose, and polyvinylpyrrolidone.
  • the weight ratio of active ingredient to solid solvent in the solid solution is not particularly restricted and can be freely chosen by the skilled person. However, it is important to choose at least as much solid solvent that the active ingredient is dissolved therein.
  • the amount of the solid solvent needed depends i.a. on the manufacturing process used. So, for example by means of melt extrusion at relatively high temperatures and high pressure a larger amount of active ingredient can be dissolved in a given amount of solvent than in simply stirring the active ingredient into the melted solvent. However, if too much active ingredient is dissolved in the solvent there is the risk that the obtained solid solution is not sufficiently stable after cooling and that the active ingredient crystallizes out again.
  • the weight ratio of dabigatran etexilate or a pharmaceutically acceptable salt thereof to solid solvent in the solid solution should be ⁇ 1 : 1 , preferably ⁇ 1 :3 and preferably ⁇ 1 :5.
  • the weight ratio may be in the range of from 1 : 1 to 1 :10, preferably in the range of from 1 : 1 to 1 :6.
  • active ingredient loadings up to 10: 1 , preferably up to 5: 1 are possible, in particular when preparing the solid solution as explained in more detail below by spray drying.
  • the solid solution in addition to the solid solvent and the active ingredient can also contain further pharmaceutical acceptable excipients.
  • the solid solution additionally contains one or more crystallization inhibitors. These have beneficial effects on the long-term storage stability of the solid solution.
  • Suitable crystallization inhibitors are inorganic or organic salts such as for example ammonium chloride. Also suitable as crystallization inhibitor is for example urea.
  • the solid solution according to the invention in addition to the active ingredient and the solid solvent, does not contain any acidic components, in particular no organic and/or inorganic acids.
  • the solid solution according to the invention may be prepared by any known method for the preparation of appropriate solid solutions.
  • the active ingredient can be dissolved in a melt of the solid solvent and subsequently, the obtained solution can be cooled.
  • dissolution of the active ingredient in the melt of the solvent is carried out by melt extrusion.
  • the obtained solid solutions can be further grinded, sieved, and either directly for example filled into capsules or first provided with additional excipients.
  • the obtained melt granulate, either directly or together with further excipients, can be compressed to tablets.
  • the solid solution according to the invention may be prepared by spray drying.
  • a further solvent for example an ethanol/water mixture and subsequently spray dried in a known manner. Since both the solid solvent and the active ingredient at first are present dissolved the spray drying conditions may be chosen such that in the obtained granulate the active ingredient is present molecularly dispersed in the solid solvent so that the spray dried granulate represents the desired solid solution.
  • the spray drying method is that the polymer may be chosen regardless of its melting point.
  • the obtained spray dried granulate can in turn optionally after grinding and sieving either directly be filled into a capsule or provided with additional excipients.
  • the spray dried granulate can be compressed to tablets either directly or together with further excipients.
  • the second embodiment of the present invention providing the dabigatran etexilate or a pharmaceutically acceptable salt thereof in a non-crystalline form is a composition comprising dabigatran etexilate or a pharmaceutically acceptable salt thereof in an amorphous form and one or more hydrophilic polymers.
  • amorphous active ingredient particles are present. The differences between the solid solution and the composition are seen for example in electron micrographs or can be determined by DSC measurements.
  • composition according to the invention should be substantially free of crystalline active ingredient particles wherein by substantially free of crystalline active ingredient particles is meant that at least 80% by weight of the active ingredient are present in an amorphous form, preferably at least 90% by weight, more preferred at least 95% by weight such as for example at least 99% by weight. Most preferably, the active ingredient is completely amorphous.
  • the dabigatran etexilate or a pharmaceutically acceptable salt thereof is present in the composition in a particle size d(90) of less than 50 pm, preferably less than 30 pm, and most preferably less than 10 pm.
  • Suitable hydrophilic polymers for the composition according to the invention are those hydrophilic polymers described above in connection with the solid solution. Also the mentioned further excipients for the solid solution may be used for the composition according to the invention.
  • the weight ratio of dabigatran etexilate or a pharmaceutically acceptable salt thereof to hydrophilic polymer in the composition according to the invention should be in the range of from 10:1 to 1 :30, preferably in the range of from 10: 1 to 1 : 10, and most preferably in the range of from 5: 1 to 1 :5.
  • the composition according to the invention is obtainable by intensively grinding the active ingredient dabigatran etexilate or a pharmaceutically acceptable salt thereof with the hydrophilic polymer. Even if the active ingredient is employed in the crystalline form by grinding in the presence of the hydrophilic polymer an amorphization of the active ingredient particles takes place. Moreover, the hydrophilic polymer stabilizes the amorphous state of the active ingredient particles so that the composition obtained after grinding is both physically and chemically stable and can be processed to pharmaceutical compositions.
  • the present invention also relates to a method for the preparation of the composition described above which comprises grinding dabigatran etexilate or a pharmaceutically acceptable salt thereof in the presence of one or more hydrophilic polymers. Grinding can be carried out as dry or wet milling. Preferably, dry milling is carried out with cooling (e.g. with liquid nitrogen). Appropriate grinding processes and suitable mills are known to the skilled person.
  • the composition in addition to active ingredient and hydrophilic polymer furthermore contains an emulsifying agent.
  • this is an emulsifying agent having a HLB value >12.
  • Suitable emulsifying agents can be of natural or synthetic origin. For example, lecithin, sodium stearylsulfate, Tween 80, Mrij, and Brij are suitable.
  • the present invention also relates to pharmaceutical compositions comprising a solid solution or composition according to the invention as described above.
  • the pharmaceutical composition may be a tablet, capsule, sachet, powder, granulate, or pellet.
  • the pharmaceutical composition can contain one or more further pharmaceutically acceptable excipients such as e.g. fillers, lubricants, flow control agents, release agents, and disintegrants.
  • excipients such as e.g. fillers, lubricants, flow control agents, release agents, and disintegrants.
  • the pharmaceutical composition can contain one or more filler(s).
  • a filler is a substance that increases the bulk volume of the mixture and thus the size of the resulting dosage form.
  • Preferred examples of fillers are lactose and calcium hydrogenphosphate.
  • the filler may be present in an amount of 0 to 80% by weight, preferred between 10 and 60% by weight of the total weight of the composition.
  • Lubricants The function of the lubricant is to ensure that the pelletizing and the ejection take place without much friction between the solids and the walls.
  • the lubricant is an alkaline-earth metal stearate or a fatty acid, such as stearic acid.
  • the lubricant is present in an amount of 0 to 2% by weight, preferably between 0.5 and 1.5% by weight of the total weight of the pharmaceutical composition.
  • Disintegrants Usually, by a disintegrant is meant a substance that is capable of breaking up the tablet into smaller pieces as soon as it is in contact with a liquid.
  • Preferred disintegrants are croscarmellose sodium, sodium carboxymethyl starch, cross-linked polyvinylpyrrolidone (crospovidon) or sodium carboxymethyl glycolate (e.g. explotab) and sodium bicarbonate.
  • the disintegrant is present in an amount of 0 to 20% by weight, preferably between 1 and 15% by weight of the total weight of the composition.
  • Flow control agents As the flow control agent there can be used e.g. colloidal silica. Preferably the flow control agent is present in an amount of 0 to 8% by weight, more preferably in an amount between 0.1 and 3% by weight of the total weight of the composition.
  • the release agent can be e.g. talcum and is present in an amount between 0 and 5% by weight, preferably in an amount between 0.5 and 3% by the weight of the composition.
  • the pharmaceutical compositions according to the invention have the advantage that the active ingredient is released from these in an essentially pH-independent manner. Without being bound by theory it is thought that this exceptional releasing behavior is ascribable to the combination of the non-crystalline form of the active ingredient with the presence of the solid solvent, in particular the hydrophilic polymer. It is thought that the active ingredient dissolves very quickly due to its non-crystalline form. Typically, here however the problem occurs that amorphous active ingredients often crystallize out again immediately after dissolution. Probably, this problem is solved by the presence of the hydrophilic polymer since the also dissolving hydrophilic polymer is possibly capable of stabilizing the oversaturated active ingredient solution in the direct environment of the pharmaceutical composition so that renewed crystallization is prevented.
  • the attached figure 1 shows the x-ray diffraction powder pattern of the market product Pradaxa ® .
  • the solid solution was prepared by melting the polymer, dissolving the active ingredient, adding the optionally present further excipients as well as subsequent cooling of the obtained melt.
  • the substances were dissolved in ethanol/water and subsequently spray dried (Buchi).
  • the active ingredient was grinded with HPMC and SDS on a Netzsch MicroCer at a number of revolutions of 3000/min. for 1 1 ⁇ 2 h in water.
  • the resulting suspension was either lyophilized, spray dried, or granulated onto a mixture of Avicel and HPMC.
  • Example 1 1 The mixture was grinded in a ball mill (Retsch) for 2 h.
  • Example 1 1 The mixture was grinded in a ball mill (Retsch) for 2 h.
  • Example 1 1 The mixture was grinded in a ball mill (Retsch) for 2 h.
  • Example 1 1 The mixture was grinded in a ball mill (Retsch) for 2 h.
  • Example 1 1 The mixture was grinded in a ball mill (Retsch) for 2 h.
  • the mixture was grinded in a ball mill (Retsch) for 2 h.

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a pharmaceutical composition containing dabigatran etexilate or a pharmaceutically acceptable salt thereof as active ingredient.

Description

Dabigatran etexilate-containing pharmaceutical composition
The present invention relates to a pharmaceutical composition containing dabigatran etexiiate or a pharmaceutically acceptable salt thereof as active ingredient.
Dabigatran etexiiate (3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]- methyl}-1 -methyl-1 H-benzimidazole-5-carbonyl)-pyridine-2-yl-amino]-propionic acid ethyl ester) has the following chemical formula:
Figure imgf000002_0001
This active ingredient is already known from WO 98/37075. The main indication field of said active ingredient is the postoperative prophylaxis of deep venous thromboses and the prophylaxis of strokes.
The solubility of the active ingredient in water is only 1.8 mg/ml. Moreover, the active ingredient has a strong pH-dependent solubility that is greatly increased in the acidic environment. This leads to the problem that conventional oral pharmaceutical compositions have large variations in the bioavailability since the solubility of the active ingredient depends on the pH value in the patient's stomach. This is particularly problematic with patients in whom the stomach pH value is changed by physiological variability, illness, or premedications (for example, PP inhibitors). There is therefore a need for oral pharmaceutical compositions of the active ingredient dabigatran etexiiate that provide a release that is independent from the pH value of the stomach and thus, provide bioavailability of the active ingredient.
WO 03/074056 suggests a pharmaceutical composition for oral application that comprises in addition to the active ingredient one or more pharmaceutically acceptable organic acids having a water solubility of >1 g/250 ml at 20°C. However, the corresponding pharmaceutical compositions may cause incompatibilities in the patient, in particular if they already have a hyperacid stomach. Moreover, the addition of the organic acid restricts the possible amount of active ingredient in an appropriate tablet or capsule. This problem is further exacerbated by the fact that, as a rule, organic acids have only a low buffer capacity so that relatively large amounts of acid have to be added to cause a possible effect on the pH value of the ambience in dissolution of an appropriate tablet.
Moreover, WO 03/074056 describes pharmaceutical compositions that are prepared by spraying a dispersion of active ingredient and binder onto a core. According to the examples, here the ratio of active ingredient to binder is 5: 1. The active ingredient is therefore used in large excess. Here, the active ingredient particles substantially remain and are still present in the crystalline form used. This is substantiated by the x-ray diffraction powder pattern of the correspondingly prepared market product Pradaxa® shown in figure 1 . There can be seen the characteristic peaks of the crystalline dabigatran etexilate.
Other pharmaceutical formulations of the active ingredient dabigatran etexilate prepared by mixing or granulation of the components are known from WO 98/37075, WO 2006/1 14415, WO 2006/131491 , and WO 2005/018615. In addition, WO 2005/028468 discloses various polymorphs of the crystalline dabigatran etexilate mesylate.
Finally, WO 2005/023249 discloses pharmaceutical compositions of the active ingredient dabigatran etexilate with a lipophilic, pharmaceutical acceptable, liquid, solid, or semi-solid carrier system. One method for the preparation of said pharmaceutical compositions is that a dispersion of active ingredient is prepared in the liquid (melted) carrier system under stirring. Under these conditions the active ingredient does not dissolve in the carrier system, but is present in the final composition as dispersion, i.e. as solid active ingredient particles embedded in the carrier system. There still remains a need for pharmaceutical compositions providing the active ingredient dabigatran etexilate in a form having a pH value-independent release as far as possible, wherein the formulation does not contain an acid as pH value-regulating agent. Moreover, the formulation shall be easy to process and provide the active ingredient both in physically and chemically stable form.
It has now surprisingly been found that these and further problems can be solved in that the active ingredient dabigatran etexilate or a pharmaceutically acceptable salt thereof is provided in a non-crystalline form. Thus, the present invention relates to dabigatran etexilate or a pharmaceutically acceptable salt thereof in non-crystalline form.
A particularly suitable pharmaceutically acceptable salt of the dabigatran etexilate is the mesylate salt, i.e. the salt of the methanesulfonic acid.
Crystalline forms can be distinguished from non-crystalline forms of the active ingredient for example by DSC measurements or x-ray diffraction powder patterns. Crystalline active ingredient particles show characteristic peaks in the x-ray diffraction powder pattern (see, for example figure 1 ) that do not occur in the non-crystalline form of the active ingredient.
The present invention provides two different non-crystalline forms of dabigatran etexilate or a pharmaceutically acceptable salt thereof. In one embodiment it is a solid solution comprising a solid solvent and dabigatran etexilate or a pharmaceutically acceptable salt thereof dissolved therein. The second embodiment provides the active ingredient in an amorphous form, this form being provided as a composition with one or more hydrophilic polymers to be stable. The solid solution differs from the composition containing the amorphous form in that in the solid solution the active ingredient is present molecularly dispersed, whereas in the composition in addition to polymer particles there are present amorphous active ingredient particles. Thus, the solid solution represents a mixture on a molecular level, whereas the composition represents a mixture of macroscopic particles.
Accordingly, by a solid solution is herein understood a body that is solid at a temperature of 23°C and a pressure of 101 kPa wherein the components are homogenously distributed. Accordingly, the active ingredient is molecularly dispersed in the solid solvent. Thus, the solid solution is substantially free of active ingredient particles wherein herein substantially free of active ingredient particles means that at least 80 % by weight of the active ingredient are dissolved in the solvent, so is present molecularly dispersed, preferably at least 90 % by weight, more preferred at least 95 % by weight such as for example at least 99 % by weight. Most preferred, the active ingredient is completely molecularly dispersed in the solvent. Any remaining active ingredient particles may be amorphous or crystalline. The molecular dispersion of the active ingredient and thus the presence of a solution can be characterized for example by electron micrographs, DSC measurements, or by a decrease of the peaks characteristic for the crystalline active ingredient particles in the x-ray diffraction powder pattern in dissolution of the crystalline active ingredient particles in the solvent.
Herein, by "solid solvent" are understood those solvents that are present as a solid at a temperature of 23°C and a pressure of 101 kPa. Suitable solid solvents for the active ingredient dabigatran etexilate or a pharmaceutical acceptable salt thereof are for example hydrophilic polymers. These can be used alone or mixed with one or more polymers.
In general, the designation "hydrophilic polymer" comprises polymers with polar groups. Examples of polar groups are hydroxy, amino, carboxy, carbonyl, ethers, esters, and sulfonates. Hydroxy groups are particularly preferred.
Preferably, the hydrophilic polymer has a water solubility of >0.01 mg/ml at 23°C.
Depending on the subsequently described methods for the preparation of the solid solution also the melting point of the hydrophilic polymer may be relevant. In the preparation by melting the solid solvent the melting point of the hydrophilic polymer should be chosen such that it is below the melting point of the active ingredient to avoid an increased degradation of the active ingredient during processing. Preferably, the melting point of the hydrophilic polymer in this case should be <140°C, more preferred <120°C. For the preparation by spray drying the polymer can be selected regardless of its melting point.
Typically, the hydrophilic polymer has an average molecular weight in the range between 1000 and 250,000 g/mol, preferably 2000 and 100,000 g/mol, and particularly preferred between 4000 and 85,000 g/mol. Further, a 2% (w/w) solution of the hydrophilic polymer in pure water has preferably a viscosity between 0.2 and 18 mPas at 25°C. The viscosity is determined in accordance to the European Pharmacopoeia (Ph. Eur.), 6th edition, section 2.2.10. Further, the hydrophilic polymer has preferably a glass transition temperature (Tg) between 20°C and 220°C, preferably 25°C to 170°C. The glass transition temperature (Tg) is the temperature at which the hydrophilic polymer becomes brittle on cooling and soft on heating. That means that the hydrophilic polymer becomes soft above the glass transition temperature and can be plastically deformed without breaking. The glass transition temperature is determined by means of a Mettler- Toledo® DSC 1 using a heating rate of 10°C/min. and a cooling rate of 15°C/min.
Examples of suitable hydrophilic polymers are cellulose derivatives, in particular hydrophilic derivatives of the cellulose (e.g. hydroxypropylmethylcellulose (HPMC), carboxymethylcellulose, preferably as sodium or calcium salt, hydroxyethylcellulose (HEC), hydroxypropylcellulose (HPC)), starch, gum arabic, tragacanth gum, polyvinylpyrrolidone (PVP), preferably with a molecular weight of from 10,000 to 60,000 g/mol, copolymers of PVP, preferably co-polymers comprising vinylpyrrolidone and vinylacetate units (e.g. povidone, VA64, BASF), preferably with a molecular weight between 40,000 and 70,000 g/mol, poly(oxyethylene) alkyl ether, poly(oxyethylene) fatty acid esters (e.g. solutol), block copolymers of ethylene oxide and propylene oxide (poloxamer, pluronic), polymethacrylate derivatives, polyvinyl alcohols, polyvinyl alcohol derivatives, polyethylene glycols, and polyethylene glycol derivatives such as polyethylene glycol glycerides and fatty acid esters of polyethylene glycol as well as sucrose fatty acid esters.
Preferred hydrophilic polymers are polyethylene glycols, polyethylene glycol glycerides, block copolymers of ethylene oxide and propylene oxide, hydroxypropylmethylcellulose, and polyvinylpyrrolidone.
The weight ratio of active ingredient to solid solvent in the solid solution is not particularly restricted and can be freely chosen by the skilled person. However, it is important to choose at least as much solid solvent that the active ingredient is dissolved therein. The amount of the solid solvent needed depends i.a. on the manufacturing process used. So, for example by means of melt extrusion at relatively high temperatures and high pressure a larger amount of active ingredient can be dissolved in a given amount of solvent than in simply stirring the active ingredient into the melted solvent. However, if too much active ingredient is dissolved in the solvent there is the risk that the obtained solid solution is not sufficiently stable after cooling and that the active ingredient crystallizes out again. In general, the weight ratio of dabigatran etexilate or a pharmaceutically acceptable salt thereof to solid solvent in the solid solution should be≤1 : 1 , preferably≤1 :3 and preferably ≤1 :5. For example, the weight ratio may be in the range of from 1 : 1 to 1 :10, preferably in the range of from 1 : 1 to 1 :6. However, also higher active ingredient loadings up to 10: 1 , preferably up to 5: 1 are possible, in particular when preparing the solid solution as explained in more detail below by spray drying.
Moreover, the solid solution in addition to the solid solvent and the active ingredient can also contain further pharmaceutical acceptable excipients. Preferably, the solid solution additionally contains one or more crystallization inhibitors. These have beneficial effects on the long-term storage stability of the solid solution. Suitable crystallization inhibitors are inorganic or organic salts such as for example ammonium chloride. Also suitable as crystallization inhibitor is for example urea.
Other suitable excipients are for example the known antioxidants.
In one embodiment the solid solution according to the invention, in addition to the active ingredient and the solid solvent, does not contain any acidic components, in particular no organic and/or inorganic acids.
In particular, in the preparation of the solid solution according to the invention by melt extrusion that is subsequently described in more detail it may be of advantage if additionally higher-melting excipients having a surface >1 ,5 m2/g are added to the solid solvent. These counteract on a eutectic melting point of the final melts. Suitable for that are for example microcrystalline cellulose, highly-disperse silica, and calcium phosphate. Also combinations of lower and higher-melting polymers can be employed.
The solid solution according to the invention may be prepared by any known method for the preparation of appropriate solid solutions. For example, the active ingredient can be dissolved in a melt of the solid solvent and subsequently, the obtained solution can be cooled. Preferably, dissolution of the active ingredient in the melt of the solvent is carried out by melt extrusion. Then, if necessary, after cooling the obtained solid solutions can be further grinded, sieved, and either directly for example filled into capsules or first provided with additional excipients. Alternatively, the obtained melt granulate, either directly or together with further excipients, can be compressed to tablets.
It may be advantageous to prepare at first a pre-emulsion by using higher-melting polymers and to process it after lyophilization.
In an alternative embodiment, the solid solution according to the invention may be prepared by spray drying. For that, both the solid solvent and the active ingredient are dissolved in a further solvent, for example an ethanol/water mixture and subsequently spray dried in a known manner. Since both the solid solvent and the active ingredient at first are present dissolved the spray drying conditions may be chosen such that in the obtained granulate the active ingredient is present molecularly dispersed in the solid solvent so that the spray dried granulate represents the desired solid solution. One advantage of the spray drying method is that the polymer may be chosen regardless of its melting point.
The obtained spray dried granulate can in turn optionally after grinding and sieving either directly be filled into a capsule or provided with additional excipients. Alternatively, the spray dried granulate can be compressed to tablets either directly or together with further excipients.
The second embodiment of the present invention providing the dabigatran etexilate or a pharmaceutically acceptable salt thereof in a non-crystalline form is a composition comprising dabigatran etexilate or a pharmaceutically acceptable salt thereof in an amorphous form and one or more hydrophilic polymers. In contrast to the solid solution in addition to particles of the hydrophilic polymer in the composition amorphous active ingredient particles are present. The differences between the solid solution and the composition are seen for example in electron micrographs or can be determined by DSC measurements.
The composition according to the invention should be substantially free of crystalline active ingredient particles wherein by substantially free of crystalline active ingredient particles is meant that at least 80% by weight of the active ingredient are present in an amorphous form, preferably at least 90% by weight, more preferred at least 95% by weight such as for example at least 99% by weight. Most preferably, the active ingredient is completely amorphous.
In a further embodiment of the composition according to the invention the dabigatran etexilate or a pharmaceutically acceptable salt thereof is present in the composition in a particle size d(90) of less than 50 pm, preferably less than 30 pm, and most preferably less than 10 pm.
Suitable hydrophilic polymers for the composition according to the invention are those hydrophilic polymers described above in connection with the solid solution. Also the mentioned further excipients for the solid solution may be used for the composition according to the invention.
In general, the weight ratio of dabigatran etexilate or a pharmaceutically acceptable salt thereof to hydrophilic polymer in the composition according to the invention should be in the range of from 10:1 to 1 :30, preferably in the range of from 10: 1 to 1 : 10, and most preferably in the range of from 5: 1 to 1 :5.
It was surprisingly found that the composition according to the invention is obtainable by intensively grinding the active ingredient dabigatran etexilate or a pharmaceutically acceptable salt thereof with the hydrophilic polymer. Even if the active ingredient is employed in the crystalline form by grinding in the presence of the hydrophilic polymer an amorphization of the active ingredient particles takes place. Moreover, the hydrophilic polymer stabilizes the amorphous state of the active ingredient particles so that the composition obtained after grinding is both physically and chemically stable and can be processed to pharmaceutical compositions.
Thus, the present invention also relates to a method for the preparation of the composition described above which comprises grinding dabigatran etexilate or a pharmaceutically acceptable salt thereof in the presence of one or more hydrophilic polymers. Grinding can be carried out as dry or wet milling. Preferably, dry milling is carried out with cooling (e.g. with liquid nitrogen). Appropriate grinding processes and suitable mills are known to the skilled person. For the stabilization of the micronized/amorphous phase of the active ingredient it may be of advantage if the composition in addition to active ingredient and hydrophilic polymer furthermore contains an emulsifying agent. Preferably, this is an emulsifying agent having a HLB value >12. Suitable emulsifying agents can be of natural or synthetic origin. For example, lecithin, sodium stearylsulfate, Tween 80, Mrij, and Brij are suitable.
The present invention also relates to pharmaceutical compositions comprising a solid solution or composition according to the invention as described above. For example, the pharmaceutical composition may be a tablet, capsule, sachet, powder, granulate, or pellet.
In addition to the present solid solvent or hydrophilic polymer the pharmaceutical composition can contain one or more further pharmaceutically acceptable excipients such as e.g. fillers, lubricants, flow control agents, release agents, and disintegrants. ("Lexikon der Hilfsstoffe fur Pharmazie, Kosmetik und angrenzende Gebiete", edited by H. P. Fiedler, 4th edition and "Handbook of Pharmaceutical Excipients", 3rd edition, edited by Arthur H. Kibbe, American Pharmaceutical Association, Washington, USA, and Pharmaceutical Press, London).
Fillers: The pharmaceutical composition can contain one or more filler(s). In general, a filler is a substance that increases the bulk volume of the mixture and thus the size of the resulting dosage form. Preferred examples of fillers are lactose and calcium hydrogenphosphate. The filler may be present in an amount of 0 to 80% by weight, preferred between 10 and 60% by weight of the total weight of the composition.
Lubricants: The function of the lubricant is to ensure that the pelletizing and the ejection take place without much friction between the solids and the walls. Preferably, the lubricant is an alkaline-earth metal stearate or a fatty acid, such as stearic acid. Typically, the lubricant is present in an amount of 0 to 2% by weight, preferably between 0.5 and 1.5% by weight of the total weight of the pharmaceutical composition.
Disintegrants: Usually, by a disintegrant is meant a substance that is capable of breaking up the tablet into smaller pieces as soon as it is in contact with a liquid. Preferred disintegrants are croscarmellose sodium, sodium carboxymethyl starch, cross-linked polyvinylpyrrolidone (crospovidon) or sodium carboxymethyl glycolate (e.g. explotab) and sodium bicarbonate. Typically, the disintegrant is present in an amount of 0 to 20% by weight, preferably between 1 and 15% by weight of the total weight of the composition.
Flow control agents: As the flow control agent there can be used e.g. colloidal silica. Preferably the flow control agent is present in an amount of 0 to 8% by weight, more preferably in an amount between 0.1 and 3% by weight of the total weight of the composition.
Release agents: The release agent can be e.g. talcum and is present in an amount between 0 and 5% by weight, preferably in an amount between 0.5 and 3% by the weight of the composition.
The pharmaceutical compositions according to the invention have the advantage that the active ingredient is released from these in an essentially pH-independent manner. Without being bound by theory it is thought that this exceptional releasing behavior is ascribable to the combination of the non-crystalline form of the active ingredient with the presence of the solid solvent, in particular the hydrophilic polymer. It is thought that the active ingredient dissolves very quickly due to its non-crystalline form. Typically, here however the problem occurs that amorphous active ingredients often crystallize out again immediately after dissolution. Probably, this problem is solved by the presence of the hydrophilic polymer since the also dissolving hydrophilic polymer is possibly capable of stabilizing the oversaturated active ingredient solution in the direct environment of the pharmaceutical composition so that renewed crystallization is prevented.
The attached figure 1 shows the x-ray diffraction powder pattern of the market product Pradaxa®.
The present invention now is explained in more detail with respect to the following examples without interpreting them as being limiting.
In examples 1 -6 the solid solution was prepared by melting the polymer, dissolving the active ingredient, adding the optionally present further excipients as well as subsequent cooling of the obtained melt. In examples 7 and 8 the substances were dissolved in ethanol/water and subsequently spray dried (Buchi).
Example 1 :
Dabigatran etexilate mesylate 86.55 mg
PEG 6000 86.55 mg
Example 2:
Dabigatran etexilate mesylate 86.55 mg
Pluronic F127 432.75 mg
Example 3:
Dabigatran etexilate mesylate 86.55 mg
Gelucire 50/13 86.55 mg
Pluronic F127 12.5 mg
Example 4:
Dabigatran etexilate mesylate 86.55 mg
Pluronic F68 25 mg
Example 5:
Dabigatran etexilate mesylate 86.55 mg
Gelucire 55/13 432.75 mg
Avicel 101 35.8 mg
Example 6:
Dabigatran etexilate mesylate 86.55 mg
PEG 6000 86.55 mg
Solutol HS 3.0 mg
Example 7:
Dabigatran etexilate mesylate 86.55 mg
HPMC (Pharmacoat 603) 86.55 mg
Solutol HS 3.0 mg Example 8:
Dabigatran etexilate mesylate 86.55 mg
Povidon VA64 200.00 mg
Example 9:
Dabigatran etexilate mesylate 86.55 mg
Pharmacoat 603 (HPMC) 17.31 mg
SDS 4.32 mg
The active ingredient was grinded with HPMC and SDS on a Netzsch MicroCer at a number of revolutions of 3000/min. for 1 ½ h in water. The resulting suspension was either lyophilized, spray dried, or granulated onto a mixture of Avicel and HPMC.
Example 10:
Dabigatran etexilate mesylate 86.55 mg
Sepitrab (Tween 80) 437.75 mg
The mixture was grinded in a ball mill (Retsch) for 2 h. Example 1 1 :
Dabigatran etexilate mesylate 86.55 mg
Lyocoat (pea starch) 200.00 mg
The mixture was grinded in a ball mill (Retsch) for 2 h.

Claims

Claims
1. Dabigatran etexilate or a pharmaceutically acceptable salt thereof in a noncrystalline form.
2. Solid solution comprising a solid solvent and dabigatran etexilate or a pharmaceutically acceptable salt thereof dissolved therein.
3. Solid solution according to claim 2, wherein the solid solvent is selected from one or more hydrophilic polymers.
4. Solid solution according to claim 3, wherein the hydrophilic polymer has an average molecular weight in the range of from 1 ,000 to 250,000 g/mol.
5. Solid solution according to claim 3 or claim 4, wherein the hydrophilic polymer has a glass transition temperature in the range of from 20°C to 220°C.
6. Solid solution according to any one of claims 3 to 5, wherein the hydrophilic polymer is selected from the group consisting of cellulose derivatives, starch, gum arabic, tragacanth gum, polyvinylpyrrolidone, copolymers of the polyvinylpyrrolidone, poly(oxyethylene) alkyl ethers, poly(oxyethylene) fatty acid esters, block-copolymers of ethylene oxide and propylene oxide, poly(methacrylate) derivatives, polyvinyl alcohols, polyvinyl alcohol derivatives, polyethylene glycols, polyethylene glycol derivatives, and sucrose fatty acid esters.
7. Solid solution according to claim 6, wherein the hydrophilic polymer is selected from the group consisting of polyethylene glycols, polyethylene glycol glycerides, block- copolymers of ethylene oxide and propylene oxide, hydroxypropylmethylcellulose, and polyvinylpyrrolidone.
8. Solid solution according to any one of claims 2 to 7, wherein the weight ratio of dabigatran etexilate or a pharmaceutically acceptable salt thereof to solid solvent≤1 :1 , preferably≤1 :5.
9. Solid solution according to any one of claims 2 to 8 further comprising a crystallization inhibitor.
10. Solid solution according to claim 9, wherein the crystallization inhibitor is selected from ammonium chloride and urea.
1 1. Composition comprising dabigatran etexilate or a pharmaceutically acceptable salt thereof in an amorphous form and one or more hydrophilic polymers.
12. Composition according to claim 1 1 , wherein the dabigatran etexilate or a pharmaceutically acceptable salt thereof is present in a particle size d(90) of less than 50 μιη.
13. Composition according to claim 1 1 or 12, wherein the hydrophilic polymer has an average molecular weight in the range of from 1 ,000 to 250,000 g/mol.
14. Composition according to any one of claims 1 1 to 13, wherein the hydrophilic polymer has a glass transition temperature in the range of from 20°C to 220°C.
15. Composition according to any one of claims 1 1 to 14, wherein the hydrophilic polymer is selected from the group consisting of cellulose derivatives, starch, gum arabic, tragacanth gum, polyvinylpyrrolidone, copolymers of the polyvinylpyrrolidone, poly(oxyethylene) alkyl ethers, poly(oxyethylene) fatty acid esters, block-copolymers of ethylene oxide and propylene oxide, poly(methacrylate) derivatives, polyvinyl alcohols, polyvinyl alcohol derivatives, polyethylene glycols, polyethylene glycol derivatives, and sucrose fatty acid esters.
16. Composition according to claim 15, wherein the hydrophilic polymer is selected from the group consisting of hydroxypropylmethylceliulose, poly(oxyethylene) sorbitan mono-oleate, and starch.
17. Composition according to any one of claims 1 1 to 16, wherein the weight ratio of dabigatran etexilate or a pharmaceutically acceptable salt thereof to hydrophilic polymer is in the range of from 10: 1 to 1 :30.
18. Composition according to any one of claims 1 1 to 17 further comprising an emulsifying agent.
19. Composition according to claim 18, wherein the emulsifying agent is selected from lecithin, sodium stearyl sulfate, Tween 80, Mrij, and Brij.
20. Method for the preparation of a solid solution according to any one of claims 2 to10 comprising the dissolution of dabigatran etexilate or a pharmaceutically acceptable salt thereof in the solvent.
21 . Method according to claim 20, wherein the dissolution is carried out in a melt of the solvent.
22. Method according to claim 21 , wherein the dissolution is carried out by means of melt extrusion.
23. Method according to claim 20, wherein the dissolution is carried out during spray drying of a solution of the solid solvent and dabigatran etexilate or a pharmaceutically acceptable salt thereof in a further solvent.
24. Method for the preparation of a composition according to any one of claims 1 1 to 19 which comprises grinding dabigatran etexilate or a pharmaceutically acceptable salt thereof in the presence of one or more hydrophilic polymers.
25. Pharmaceutical composition comprising a solid solution according to any one of claims 2 to 10 or a composition according to any one of claims 1 1 to 19.
26. Pharmaceutical composition according to claim 25 in the form of a tablet, capsule, sachet, powder, granulate, or pellet.
PCT/EP2011/053236 2010-03-08 2011-03-03 Dabigatran etexilate-containing pharmaceutical composition Ceased WO2011110478A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US13/583,273 US20130149346A1 (en) 2010-03-08 2011-03-03 Dabigatran etexilate-containing pharmaceutical composition
JP2012556453A JP2013521318A (en) 2010-03-08 2011-03-03 Pharmaceutical composition containing dabigatran etexilate
EP11708231A EP2545044A1 (en) 2010-03-08 2011-03-03 Dabigatran etexilate-containing pharmaceutical composition
EA201201263A EA201201263A1 (en) 2010-03-08 2011-03-03 PHARMACEUTICAL COMPOSITION CONTAINING DAGIGATRAN ETEXYLATE
CA2792273A CA2792273A1 (en) 2010-03-08 2011-03-03 Dabigatran etexilate-containing pharmaceutical composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10155783.3 2010-03-08
EP10155783 2010-03-08

Publications (1)

Publication Number Publication Date
WO2011110478A1 true WO2011110478A1 (en) 2011-09-15

Family

ID=43827124

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/053236 Ceased WO2011110478A1 (en) 2010-03-08 2011-03-03 Dabigatran etexilate-containing pharmaceutical composition

Country Status (6)

Country Link
US (1) US20130149346A1 (en)
EP (1) EP2545044A1 (en)
JP (1) JP2013521318A (en)
CA (1) CA2792273A1 (en)
EA (1) EA201201263A1 (en)
WO (1) WO2011110478A1 (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012077136A3 (en) * 2010-12-06 2012-10-04 Msn Laboratories Limited Process for the preparation of benzimidazole derivatives and its salts
WO2013110567A1 (en) * 2012-01-24 2013-08-01 Boehringer Ingelheim International Gmbh Novel orally administered dabigatran formulation
EP2631234A1 (en) 2012-02-23 2013-08-28 Esteve Química, S.A. Solid forms of dabigatran etexilate mesylate and processes for their preparation
WO2014020546A2 (en) 2012-07-31 2014-02-06 Ranbaxy Laboratories Limited Crystalline forms of dabigatran etexilate and process for their preparation
WO2013132457A3 (en) * 2012-03-07 2014-02-27 National Institute Of Pharmaceutical Education And Research (Niper) Nanocrystalline solid dispersion compositions and process of preparation thereof
WO2014033693A1 (en) 2012-08-31 2014-03-06 Ranbaxy Laboratories Limited Process for the preparation of crystalline form i of methanesulfonate salt of dabigatran etexilate
WO2014049585A2 (en) 2012-09-28 2014-04-03 Ranbaxy Laboratories Limited Process for the preparation of dabigatran etexilate or pharmaceutically acceptable salt thereof
WO2014049586A2 (en) 2012-09-28 2014-04-03 Ranbaxy Laboratories Limited Process for the preparation of dabigatran etexilate or pharmaceutically acceptable salt thereof
WO2014178017A1 (en) 2013-04-30 2014-11-06 Ranbaxy Laboratories Limited Dabigatran etexilate impurity, process of its preparation, and its use as a reference standard
CN104274410A (en) * 2013-07-04 2015-01-14 江苏豪森药业股份有限公司 Pharmaceutical composition containing dabigatran etexilate or salt of dabigatran etexilate
EP2835370A1 (en) 2013-08-08 2015-02-11 Medichem, S.A. New crystals of dabigatran etexilate mesylate
WO2015071841A1 (en) * 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
CN104644543A (en) * 2014-12-25 2015-05-27 青岛黄海制药有限责任公司 Dabigatran-containing solid dispersion and preparation method as well as application thereof
CN104873474A (en) * 2015-05-19 2015-09-02 广州南新制药有限公司 Methanesulfonic acid dabigatran oral solid preparation
EP2836206A4 (en) * 2012-04-10 2015-11-04 Rubicon Res Private Ltd Controlled release pharmaceutical formulations of direct thrombin inhibitors
US9273030B2 (en) 2012-04-02 2016-03-01 Msn Laboratories Private Limited Process for the preparation of benzimidazole derivatives and salts thereof
CN106491553A (en) * 2016-12-09 2017-03-15 吉林省博大伟业制药有限公司 A kind of new synthesis process of dabigatran etexilate methanesulfonate
CN106880845A (en) * 2015-12-10 2017-06-23 贵州益佰制药股份有限公司 A kind of dabigatran etcxilate solid dispersions enteric coated preparations and preparation method thereof

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111012756B (en) * 2013-06-21 2023-06-13 四川海思科制药有限公司 Dabigatran etexilate pharmaceutical composition and preparation method thereof
US12133911B2 (en) 2015-06-09 2024-11-05 Capsugel Belgium Nv Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
JP2019014712A (en) * 2017-07-03 2019-01-31 エルメッド エーザイ株式会社 Stable dabigatran formulation
CN110339193B (en) 2018-04-04 2022-04-29 上海汉都医药科技有限公司 Pharmaceutical composition containing dabigatran etexilate and preparation method thereof
CN114191394A (en) * 2020-09-02 2022-03-18 北京四环制药有限公司 Dabigatran etexilate pharmaceutical composition, preparation method and application thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037075A1 (en) 1997-02-18 1998-08-27 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, their production and use as medicaments
WO2003074056A1 (en) 2002-03-07 2003-09-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Form of presentation for 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] propionic acid ethyl ester to be administered orally
WO2005018615A1 (en) 2003-08-16 2005-03-03 Boehringer Ingelheim International Gmbh Tablet containing 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]- methyl}-1-methyl-1h-benzimidazolo-5-carbonyl)-pyridino-2-yl- amino]-ethyl propionate or the salts thereof
WO2005023249A1 (en) 2003-09-03 2005-03-17 Boehringer Ingelheim International Gmbh Novel orally administered dosage form for 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] -ethyl proprionate and salts thereof
WO2005028468A1 (en) 2003-08-29 2005-03-31 Boehringer Ingelheim International Gmbh 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridine-2-yl-amino]-propionic acid ethyl ester methane sulphonate and use thereof as a medicament
WO2006114415A2 (en) 2005-04-27 2006-11-02 Boehringer Ingelheim International Gmbh Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazole-5-carbonyl)-pyridin-2-yl-amino] propionic acid ethyl ester
WO2006131491A1 (en) 2005-06-04 2006-12-14 Boehringer Ingelheim International Gmbh Polymorphs of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-iminomethyl)phenylamino]methyl}-1-methyl-1h-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate
DE102005061624A1 (en) * 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Improved process for the preparation of salts of 4- (benzimidazolylmethylamino) -benzamidines
EP2105130A1 (en) * 2008-03-25 2009-09-30 Ratiopharm GmbH Pharmaceutical formula and method for its production

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4151273A (en) * 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
US5340591A (en) * 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
US5514663A (en) * 1993-10-19 1996-05-07 The Procter & Gamble Company Senna dosage form
AU763309B2 (en) * 1998-07-20 2003-07-17 Smithkline Beecham Corporation Bioenhanced formulations comprising eprosartan in oral solid dosage form
IT1320176B1 (en) * 2000-12-22 2003-11-26 Nicox Sa SOLID DISPERSIONS OF NITRATED ACTIVE INGREDIENTS.
US20070099996A1 (en) * 2003-05-20 2007-05-03 Shashikanth Isloor Pharmaceutical compositions of acitretin
EP1711564A2 (en) * 2003-12-06 2006-10-18 BASF Coatings AG Hardenable materials, containing disagglomerated barium sulfate, method for production and use thereof
US20060134188A1 (en) * 2004-12-20 2006-06-22 Hans-Peter Podhaisky Transdermal pharmaceutical preparation with a progesterone A-specific ligand (PRASL) as active ingredient
BRPI0621027A2 (en) * 2006-01-13 2011-11-29 Pharmacyclics Inc compound, pharmaceutical composition
PL2526933T3 (en) * 2006-09-22 2015-08-31 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037075A1 (en) 1997-02-18 1998-08-27 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, their production and use as medicaments
WO2003074056A1 (en) 2002-03-07 2003-09-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Form of presentation for 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] propionic acid ethyl ester to be administered orally
WO2005018615A1 (en) 2003-08-16 2005-03-03 Boehringer Ingelheim International Gmbh Tablet containing 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]- methyl}-1-methyl-1h-benzimidazolo-5-carbonyl)-pyridino-2-yl- amino]-ethyl propionate or the salts thereof
WO2005028468A1 (en) 2003-08-29 2005-03-31 Boehringer Ingelheim International Gmbh 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridine-2-yl-amino]-propionic acid ethyl ester methane sulphonate and use thereof as a medicament
WO2005023249A1 (en) 2003-09-03 2005-03-17 Boehringer Ingelheim International Gmbh Novel orally administered dosage form for 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] -ethyl proprionate and salts thereof
WO2006114415A2 (en) 2005-04-27 2006-11-02 Boehringer Ingelheim International Gmbh Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazole-5-carbonyl)-pyridin-2-yl-amino] propionic acid ethyl ester
WO2006131491A1 (en) 2005-06-04 2006-12-14 Boehringer Ingelheim International Gmbh Polymorphs of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-iminomethyl)phenylamino]methyl}-1-methyl-1h-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate
DE102005061624A1 (en) * 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Improved process for the preparation of salts of 4- (benzimidazolylmethylamino) -benzamidines
EP2105130A1 (en) * 2008-03-25 2009-09-30 Ratiopharm GmbH Pharmaceutical formula and method for its production

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"European Pharmacopoeia"
"Handbook of Pharmaceutical Excipients", AMERICAN PHARMACEUTICAL ASSOCIATION
"Lexikon der Hilfsstoffe fur Pharmazie, Kosmetik und angrenzende Gebiete"
LEUNER C ET AL: "Improving drug solubility for oral delivery using solid dispersions", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 50, no. 1, 3 July 2000 (2000-07-03), pages 47 - 60, XP004257179, ISSN: 0939-6411, DOI: DOI:10.1016/S0939-6411(00)00076-X *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006448B2 (en) 2010-12-06 2015-04-14 Msn Laboratories Private Limited Process for the preparation of benzimidazole derivatives and its salts
WO2012077136A3 (en) * 2010-12-06 2012-10-04 Msn Laboratories Limited Process for the preparation of benzimidazole derivatives and its salts
WO2013110567A1 (en) * 2012-01-24 2013-08-01 Boehringer Ingelheim International Gmbh Novel orally administered dabigatran formulation
EP2631234A1 (en) 2012-02-23 2013-08-28 Esteve Química, S.A. Solid forms of dabigatran etexilate mesylate and processes for their preparation
WO2013124385A2 (en) 2012-02-23 2013-08-29 Esteve Química, S.A. Solid forms of dabigatran etexilate mesylate and processes for their preparation
US9073899B2 (en) 2012-02-23 2015-07-07 Esteve Química, S.A. Solid forms of dabigatran etexilate mesylate and processes for their preparation
WO2013132457A3 (en) * 2012-03-07 2014-02-27 National Institute Of Pharmaceutical Education And Research (Niper) Nanocrystalline solid dispersion compositions and process of preparation thereof
US9801855B2 (en) 2012-03-07 2017-10-31 National Institute Of Pharmaceutical Education And Research (Niper) Nanocrystalline solid dispersion compositions and process of preparation thereof
US9273030B2 (en) 2012-04-02 2016-03-01 Msn Laboratories Private Limited Process for the preparation of benzimidazole derivatives and salts thereof
EP2836206A4 (en) * 2012-04-10 2015-11-04 Rubicon Res Private Ltd Controlled release pharmaceutical formulations of direct thrombin inhibitors
WO2014020546A2 (en) 2012-07-31 2014-02-06 Ranbaxy Laboratories Limited Crystalline forms of dabigatran etexilate and process for their preparation
WO2014033693A1 (en) 2012-08-31 2014-03-06 Ranbaxy Laboratories Limited Process for the preparation of crystalline form i of methanesulfonate salt of dabigatran etexilate
US9150542B2 (en) 2012-08-31 2015-10-06 Ranbaxy Laboratories Limited Process for the preparation of crystalline form I of methanesulfonate salt of dabigatran etexilate
WO2014049585A2 (en) 2012-09-28 2014-04-03 Ranbaxy Laboratories Limited Process for the preparation of dabigatran etexilate or pharmaceutically acceptable salt thereof
WO2014049586A2 (en) 2012-09-28 2014-04-03 Ranbaxy Laboratories Limited Process for the preparation of dabigatran etexilate or pharmaceutically acceptable salt thereof
WO2014178017A1 (en) 2013-04-30 2014-11-06 Ranbaxy Laboratories Limited Dabigatran etexilate impurity, process of its preparation, and its use as a reference standard
CN104274410A (en) * 2013-07-04 2015-01-14 江苏豪森药业股份有限公司 Pharmaceutical composition containing dabigatran etexilate or salt of dabigatran etexilate
EP2835370A1 (en) 2013-08-08 2015-02-11 Medichem, S.A. New crystals of dabigatran etexilate mesylate
WO2015071841A1 (en) * 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
CN104644543A (en) * 2014-12-25 2015-05-27 青岛黄海制药有限责任公司 Dabigatran-containing solid dispersion and preparation method as well as application thereof
CN104873474A (en) * 2015-05-19 2015-09-02 广州南新制药有限公司 Methanesulfonic acid dabigatran oral solid preparation
CN106880845A (en) * 2015-12-10 2017-06-23 贵州益佰制药股份有限公司 A kind of dabigatran etcxilate solid dispersions enteric coated preparations and preparation method thereof
CN106491553A (en) * 2016-12-09 2017-03-15 吉林省博大伟业制药有限公司 A kind of new synthesis process of dabigatran etexilate methanesulfonate

Also Published As

Publication number Publication date
CA2792273A1 (en) 2011-09-15
EA201201263A1 (en) 2013-04-30
US20130149346A1 (en) 2013-06-13
EP2545044A1 (en) 2013-01-16
JP2013521318A (en) 2013-06-10

Similar Documents

Publication Publication Date Title
US20130149346A1 (en) Dabigatran etexilate-containing pharmaceutical composition
ES2993251T3 (en) Pharmaceutical compositions of nilotinib
EP2068839B1 (en) Pharmaceutical compositions comprising nilotinib or its salt
KR100634953B1 (en) Formulations in biologically enhanced oral solid dosage forms comprising eprosartan
JP5147703B2 (en) Solid pharmaceutical dosage form that can be administered orally and has a rapid release of the active ingredient
EP2542224B1 (en) Dabigatran etexilate-containing oral pharmaceutical composition
JP5833037B2 (en) Bilayer tablet containing telmisartan and diuretic
EP2303240A1 (en) Pharmaceutical compositions comprising 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
WO2015124995A1 (en) Solid dosage forms of rivaroxaban
US8940757B2 (en) Prasugrel in micronized, crystalline form and pharmaceutical composition thereof
WO2015145462A1 (en) Pharmaceutical compositions of dabigatran
WO2022115464A1 (en) Amorphous cabozantinib particles and uses thereof
US20160120870A1 (en) The process for the preparation of a pharmaceutical composition comprising rivaroxaban
RS62422B1 (en) Pharmaceutical compositions comprising phenylaminopyrimidine derivative
US9403842B2 (en) Prasugrel in non-crystalline form and pharmaceutical composition thereof
KR102707060B1 (en) Stability and bioavailability enhanced solid dispersion formulations of Olaparib
KR101441450B1 (en) Eprosartan solid dispersant improved bioavailability, its fabrication method and the use
WO2016139683A2 (en) Pharmaceutical compositions of lurasidone and process for preparing the same
WO2007024123A1 (en) Pharmaceutical composition of pranlukast solid-dispersion with improved initial dissolution rate and the method of preparing the same
KR101956586B1 (en) Pharmaceutical composition and preparation method thereof
WO2022162687A1 (en) Pharmaceutical compositions comprising nilotinib
HK40070844B (en) Pharmaceutical compositions comprising nilotinib
EP4026540A1 (en) A film coated tablet comprising apixaban
HK1133193B (en) Pharmaceutical compositions comprising nilotinib or its salt

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11708231

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2011708231

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2792273

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 221817

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2012556453

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 201201263

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 13583273

Country of ref document: US